WuXi XDC — a joint venture between WuXi Biologics and WuXi STA — is a global CRDMO focused on the antibody–drug conjugate (ADC) and broader bioconjugate markets, dedicated to providing fully integrated services from concept development through commercialization. The company provides single-source discovery, development, and manufacturing services for ADCs and other novel bioconjugates, from drug substances through to the final drug product.